Impact of Alopecia Areata on Major Life-changing Decisions: Prevalence and Associated Factors
DOI:
https://doi.org/10.2340/actadv.v105.43039Keywords:
Alopecia areata, Quality of life, Major life-changing decisionsAbstract
Alopecia areata is a prevalent autoimmune condition causing non-scarring alopecia, with significant impacts on quality of life. However, the long-term effects on major life-changing decisions remain understudied. A cross-sectional study was performed including patients with alopecia areata who attended the Dermatology Department of the Virgen de las Nieves University Hospital. Patients were asked to complete questionnaires to assess the impact of alopecia areata on major life-changing decisions and quality of life. A total of 70 patients were included: 71% were female and 29% were male. The mean age was 38.70 (SD 14.32). The most affected major life-changing decisions were couple relationships and dressing; followed by job performance, social relationships, lifestyle changes, and sports practice. Female gender, higher therapeutic burden, or Dermatology Life Quality Index scores, and lower World Health Organization Five Well Being Index rating were significantly associated with greater major life-changing decisions impairment (p < 0.05). Disease severity and duration did not correlate with increased impact in most major life-changing decisions (p > 0.10). In conclusion, there are some major life-changing decisions that appear to be significantly affected in patients with alopecia areata. The identification of factors associated such us female gender, therapeutic burden, or alterations in mental well-being is crucial to explore and limit the long-term negative effects of the disease.
Downloads
References
Sibbald C. Alopecia areata: an updated review for 2023. J Cutan Med Surg 2023; 27: 241–259. DOI: https://doi.org/10.1177/12034754231168839
Alhanshali L, Buontempo MG, Lo Sicco KI, Shapiro J. Alopecia areata: burden of disease, approach to treatment, and current unmet needs. Clin Cosmet Investig Dermatol 2023; 16: 803–820. DOI: https://doi.org/10.2147/CCID.S376096
Wei D, Chen Y, Shen Y, Xie B, Song X. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis. Front Immunol 2023; 14: 1152513. DOI: https://doi.org/10.3389/fimmu.2023.1152513
Vañó-Galván S, Blume-Peytavi U, Farrant P, Reygagne P, Johansson E, Reed C, et al. Physician- and patient-reported severity and quality of life impact of alopecia areata: results from a real-world survey in five European countries. Dermatol Ther 2023; 13: 3121–3135. DOI: https://doi.org/10.1007/s13555-023-01057-0
Lauron S, Plasse C, Vaysset M, D’Incan M, Rondepierre F, Jalenques I. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol 2023; 159: 281–288. DOI: https://doi.org/10.1001/jamadermatol.2022.6085
Sánchez-Díaz M, Díaz-Calvillo P, Ureña-Paniego CA, Molina-Leyva A, Arias-Santiago S. Quality of life and mood status disturbances in cohabitants of patients with alopecia areata: a cross-sectional study in a Spanish population. Int J Environ Res Public Health 2022; 19: 16323. DOI: https://doi.org/10.3390/ijerph192316323
Sánchez-Díaz M, Montero-Vílchez T, Cuenca-Barrales C, Molina-Leyva A, Arias-Santiago S. Prevalence and implications of type D personality in patients with alopecia areata: a marker of quality-of-life impairment and mood status disturbances, a comparative study. J Eur Acad Dermatol Venereol 2023; 37: 1064–1070. DOI: https://doi.org/10.1111/jdv.18733
Mayer KU. New directions in life course research. Annu Rev Sociol 2009; 35: 413–433. DOI: https://doi.org/10.1146/annurev.soc.34.040507.134619
Lynch J, Smith GD. A life course approach to chronic disease epidemiology. Annu Rev Public Health 2005; 26: 1–35. DOI: https://doi.org/10.1146/annurev.publhealth.26.021304.144505
Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. Int J Epidemiol 2002; 31: 285–293. DOI: https://doi.org/10.1093/ije/31.2.285
Kimball A, Gieler U, Linder D, Sampogna F, Warren R, Augustin M. Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989–1004. DOI: https://doi.org/10.1111/j.1468-3083.2010.03705.x
Bhatti Z, Salek M, Finlay A. Major life changing decisions and cumulative life course impairment. J Eur Acad Dermatol Venereol 2011; 25: 245–246. DOI: https://doi.org/10.1111/j.1468-3083.2010.03930.x
Krüger C, Schallreuter KU. Cumulative life course impairment in vitiligo. Curr Probl Dermatol 2013; 44: 102–117. DOI: https://doi.org/10.1159/000350010
Augustin M. Cumulative life course impairment in chronic wounds. Curr Probl Dermatol 2013; 44: 125–129. DOI: https://doi.org/10.1159/000350789
Fine JD. Cumulative life course impairment by epidermolysis bullosa. Curr Probl Dermatol 2013; 44: 91–101. DOI: https://doi.org/10.1159/000350009
Piaserico S. Cumulative life course impairment in melanoma and nonmelanoma skin cancer. Curr Probl Dermatol 2013; 44: 118–124. DOI: https://doi.org/10.1159/000350055
Burns LJ, Mesinkovska N, Kranz D, Ellison A, Senna MM. Cumulative life course impairment of alopecia areata. Int J Trichology 2020; 12: 197–204. DOI: https://doi.org/10.4103/ijt.ijt_99_20
Jebb AT, Ng V, Tay L. A review of key Likert scale development advances: 1995–2019. Front Psycho 2021; 12: 637547. DOI: https://doi.org/10.3389/fpsyg.2021.637547
Bhatti ZU, Salek SS, Bolton CE, George L, Halcox JP, Jones S, et al. The development and validation of the major life changing decision profile (MLCDP). Health Qual Life Outcomes 2013; 11: 78. DOI: https://doi.org/10.1186/1477-7525-11-78
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216. DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
de Tiedra AG, Mercadal J, Badía X, Mascaró JM, Herdman M, Lozano R. Adaptación transcultural al español del cuestionario Dermatology Life Quality Index (DLQI): El Índice de Calidad de Vida en Dermatología. Actas Dermo-Sifiliográficas 1998; 89: 692–700.
Carrozzino D, Christensen KS, Patierno C, Woźniewicz A, Møller SB, Arendt ITP, et al. Cross-cultural validity of the WHO-5 Well-Being Index and Euthymia Scale: a clinimetric analysis. J Affect Disord 2022; 311: 276–283. DOI: https://doi.org/10.1016/j.jad.2022.05.111
Psykiatric Center North Zealand. WHO‑5 Questionnaires [Internet]. Hillerød (Denmark): Region Hovedstadens Psykiatri. Available from: https://www.psykiatri-regionh.dk/who-5/who-5-questionnaires/Pages/default.aspx
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361–370. DOI: https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
Vilela-Estrada AL, Villarreal-Zegarra D, Copez-Lonzoy A, Esenarro-Valencia L, Sánchez-Ramírez JC, Lamas-Delgado F, et al. Psychometric properties of the Spanish version of the hospital anxiety and depression scale in cancer patients. Front Psychol. 2024; 15: 1497946. DOI: https://doi.org/10.3389/fpsyg.2024.1497946
Olsen EA, Canfield D. SALT II: a new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. J Am Acad Dermatol 2016; 75: 1268–1270. DOI: https://doi.org/10.1016/j.jaad.2016.08.042
Haselgruber S, Muñoz-Barba D, Leon-Pérez FJ, Cuenca-Barrales C, Arias-Santiago S, Molina-Leyva A. Therapeutic burden in hidradenitis suppurativa: a cross-sectional study of 557 patients. Int J Dermatol 2025; 64: 539–545. DOI: https://doi.org/10.1111/ijd.17517
Li SJ, Huang KP, Joyce C, Mostaghimi A. The impact of alopecia areata on sexual quality of life. Int J Trichology 2018; 10: 271–274. DOI: https://doi.org/10.4103/ijt.ijt_93_18
Cash TF. The psychology of hair loss and its implications for patient care. Clin Dermatol 2001; 19(2): 161–166. DOI: https://doi.org/10.1016/S0738-081X(00)00127-9
Kacar SD, Soyucok E, Bagcioglu E, Ozuguz P, Coskun KS, Asık AH, et al. The perceived stigma in patients with alopecia and mental disorder: a comparative study. Int J Trichology 2016; 8: 135–140. DOI: https://doi.org/10.4103/0974-7753.189005
Macbeth AE, Holmes S, Harries M, Chiu WS, Tziotzios C, de Lusignan S, et al. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. Br J Dermatol 2022; 187: 73–81. DOI: https://doi.org/10.1111/bjd.21055
Aldhouse NVJ, Kitchen H, Knight S, Macey J, Nunes FP, Dutronc Y, et al. “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient-Rep Outcomes 2020; 4: 76. DOI: https://doi.org/10.1186/s41687-020-00240-7
Senna M, Ko J, Glashofer M, Walker C, Ball S, Edson-Heredia E, et al. Predictors of QOL in patients with alopecia areata. J Invest Dermatol 2022; 142: 2646–2650.e3. DOI: https://doi.org/10.1016/j.jid.2022.02.019
Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc 2020; 20: S62–S68. DOI: https://doi.org/10.1016/j.jisp.2020.05.007
von Stülpnagel CC, Augustin M, Düpmann L, da Silva N, Sommer R. Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases: a systematic review. J Eur Acad Dermatol Venereol 2021; 35: 2166–2184. DOI: https://doi.org/10.1111/jdv.17348
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Daniel Muñoz-Barba, Alberto Soto-Moreno, Sofía Haselgruber-de Francisco, Manuel Sánchez-Díaz, Salvador Arias-Santiago
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
